| Literature DB >> 20028528 |
Elisabetta Nucleo1, Laura Steffanoni, Giulia Fugazza, Roberta Migliavacca, Ernesto Giacobone, Antonella Navarra, Laura Pagani, Paolo Landini.
Abstract
BACKGROUND: Acinetobacter baumannii is emerging as an important nosocomial pathogen. Multidrug resistance, as well as ability to withstand environmental stresses, makes eradication of A. baumannii difficult, particularly from hospital settings.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20028528 PMCID: PMC2804601 DOI: 10.1186/1471-2180-9-270
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Antimicrobial susceptibility, production of β-lactamases, and pulsotype of the 69 isolates of A. baumannii analyzed in this study.
| MIC Method Phoenix (μg/ml)b | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | Hospital | Sample Source | Ward/unita | TE | A/S | CI | AK | GM | PP | PT | AT | CZ | CP | IP | MP | MIC IP (μg/ml) | β-lactamases | Pulsotype |
| 2 | S. Matteo | Blood | Medicine | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >32 | >16 | ≤1 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL |
| 6 | S. Matteo | Sputum | Medicine | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >32 | >16 | ≤1 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Matteo | Urine | Medicine | 4 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | / | 2 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL |
| 6 | S. Matteo | Soft tissue swab | Medicine | 4 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL, SMAL 2, |
| 3 | S. Matteo | Bronchoaspirate | Medicine | / | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL, SMAL 3 |
| 3 | S. Matteo | Urine | Surgery | 4 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | / | 2 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL |
| 8 | S. Matteo | Wound swab | Surgery | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL |
| 8 | S. Matteo | Blood | Surgery | / | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | / | 2 | ≤1 | 0.5-1.0 | AmpC, OXA-90, OXA-10 | SMAL, SMAL 1 |
| 1 | S. Matteo | Pus | Surgery | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Sputum | Surgery | / | 4/2 | >2 | >32 | >8 | >64 | 64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Soft tissue swab | LTCU | ≤2 | / | >2 | >32 | >8 | >64 | 64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Sputum | LTCU | / | / | >2 | >32 | >8 | >64 | 64/4 | >16 | >16 | >16 | 2 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Blood | LTCU | / | / | >2 | 32 | >8 | >64 | 64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Matteo | Soft tissue swab | Dermatology | ≤2 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5-1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Pus | Dermatology | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤ | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Matteo | Wound swab | Ambulatory | / | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | 4 | 2 | 2 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Urine | Ambulatory | ≤2 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | / | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Matteo | Wound swab | Urology | ≤2 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Matteo | Urine | Nephrology | / | / | >2 | >32 | >16 | >64 | >64/4 | >16 | >16 | / | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Matteo | Blood | Haematology | 8 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | 16 | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Maugeri | Bronchoaspirate | PRU | 8 | / | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | / | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 7 | S. Maugeri | Urine | NRU | / | / | >2 | >32 | >8 | >64 | 64/4 | >16 | >16 | / | ≤1 | ≤1 | 1 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Maugeri | Skin swab | NRU | / | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >16 | >16 | ≤1 | ≤1 | 0.5 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Maugeri | Bronchoaspirate | NRU | ≤2 | / | >2 | >32 | >8 | >64 | 64/4 | >16 | >32 | / | ≤1 | ≤1 | 0.5-1 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Maugeri | Urine | ORU | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >32 | / | ≤1 | ≤1 | 0.5 | AmpC, OXA-90, OXA-10 | SMAL |
| 1 | S. Maugeri | Skin swab | ORU | ≤2 | 8/4 | >2 | >32 | >8 | >64 | 64/4 | >16 | >32 | / | ≤1 | ≤1 | 0.5 | AmpC, OXA-90, OXA-10 | SMAL |
| 2 | S. Maugeri | Urine | FRU | ≤2 | 8/4 | >2 | >32 | >8 | >64 | >64/4 | >16 | >32 | >16 | ≤1 | ≤1 | 0.5 | AmpC, OXA-90, OXA-10 | SMAL |
a PRU, pulmonary rehabilitation unit; NRU, neurological rehabilitation unit; ORU, oncological rehabilitation unit. b TE, tetracicline; A/S, ampicillin/sulbactam; CI, ciprofloxacin; AK, amikacin; GM, gentamicin; PP, piperacillin; PT, piperacillin/tazobactam; AT, aztreonam; CZ, ceftazidime; CP, cefepime; IP, imipenem; MP, meropenem. Ditto marks indicate that the β-lactamase pattern was identical for all the strains tested.
Figure 1PFGE profiles of . 5 of the 69 isolates identified in this study and analyzed by PFGE are shown (Lanes 1-5). Lane 1, Isolate from urine sample (see Table 1, line 22); Lane 2: Isolate from soft tissue swab (Table 1, line 4); Lane 3: Isolate from blood sample (Table 1, line 8); Lane 4: Isolate from wound swab (Table 1, line 7); Lane 5: Isolate from bronchoaspirate sample (Table 1, Line 5). Isolates were compared to strains representative of European clones I (RUH875, Lane 7) and II (RUH134, Lane 6). Strains belonging to the same clone are clustered at a level of 80% by PFGE with the parameters used as shown by the dendrogram analysis shown on the left.
Figure 2A. Surface adhesion to polystyrene microtiter plates by . Black bars bacterial cultures grown in LB medium; light grey bars LB1/4 medium; white bars M9Glu/sup; dark grey bars M9Suc/sup. B. Binding of Calcofluor to . The horizontal dotted line indicates the 50% inhibition mark. IC50's values are indicated by vertical dotted lines.
Figure 3Transmission electron microscopy images of . Panel A: A. baumannii cells resuspended from biofilm 10,000× magnification. The bundle-like fibers embedding the bacterial cells are indicated by the arrow. Panel B: A. baumannii cells resuspended from biofilm and treated with 1 Unit cellulase for 30 minutes, 12,000× magnification.
Figure 4Surface adhesion by . Grey bars: untreated samples; black bars: samples treated with 1 Unit cellulase.
Figure 5SDS-PAGE of membrane fractions of : the arrows point to the 70 KDa bands showing different levels of expression in cultures treated with imipenem. The band at ca. 40 KDa was identified by MALDI-TOF as OmpA the major outer membrane protein in A. baumannii. Molecular Weight standards are shown.
Identification of membrane proteins induced by exposure to subinhibitory imipenem concentrations.
| Protein identified by MALDI-TOF and/or corresponding gene in | Expected Molecular Weight (KDa) | Protein function | Conditions in which proteins are produced | Gene expression in the presence of imipenem (fold induction) |
|---|---|---|---|---|
| OprC (A1S_0170) | 67,700 | Putative outer membrane copper receptor | Both in control and in imipenem-induced cultures | N.D. |
| (A1S_1921) | 71,742 | Ferrichrome-iron receptor | Imipenem-induced cultures | 3.51 |
| (A1S_1063) | 73,034 | TonB-dependent siderophore receptor | Imipenem-induced cultures | 3.39 |
Genes encoding the identified proteins are identified with the annotation number for A. baumanni ATCC 17978 strain [52].
Figure 6Surface adhesion by . Grey bars: untreated samples; black bars: samples treated with 1 Unit cellulase.